Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and low-dose cytarabine in elderly AML or high-risk MDS
NCT00516828Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Canadian Cancer Trials Group. Started Nov 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00516828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516828.